Free Trial
NASDAQ:ONC

BeOne Medicines 8/6/2025 Earnings Report

BeOne Medicines logo
$298.29 -0.23 (-0.08%)
As of 08/7/2025 04:00 PM Eastern

BeOne Medicines EPS Results

Actual EPS
$0.84
Consensus EPS
$0.48
Beat/Miss
Beat by +$0.36
One Year Ago EPS
N/A

BeOne Medicines Revenue Results

Actual Revenue
$1.32 billion
Expected Revenue
$1.24 billion
Beat/Miss
Beat by +$76.45 million
YoY Revenue Growth
N/A

BeOne Medicines Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BeOne Medicines Earnings Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript
See More BeOne Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email.

About BeOne Medicines

BeOne Medicines (NASDAQ:ONC) Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

View BeOne Medicines Profile

More Earnings Resources from MarketBeat